DCOY is trading 7.2% down at $5.49 after the company received SEC effectiveness for its S-1 registration, clearing the way for its planned IPO and related securities offering.
- Traders appear to be digesting potential dilution and increased supply following Decoy Therapeutics’ recent registration and effectiveness filings.
- The move is primarily company-specific, as broader U.S. indices are only slightly lower during the session.